Djuric Stevan W, Grihalde Nelson, Lin Chun Wel
Metabolic Diseases Research, R4CB, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, IL 60064, USA.
Curr Opin Investig Drugs. 2002 Nov;3(11):1617-23.
As the incidence of Type II diabetes (T2DM) will increase to 200 million cases worldwide by 2010, the search for new, effective agentsfor its treatment has been pushed into overdrive. According to Unger's bihormonal hypothesis, elevated levels of circulating glucagon in T2DM patients results in increased rates of hepatic glucose synthesis and glycogen metabolism, translating to excessive plasma glucose levels. In this context, considerable efforts have been made to identify glucagon antagonists for the treatment of T2DM. This review reflects research in this area from 1999 to 2002.
到2010年,全球II型糖尿病(T2DM)的发病率将增至2亿例,因此,寻找治疗该病的新型有效药物已进入白热化阶段。根据昂格尔的双激素假说,T2DM患者体内循环胰高血糖素水平升高,导致肝脏葡萄糖合成和糖原代谢速率加快,进而造成血糖水平过高。在此背景下,人们为确定用于治疗T2DM的胰高血糖素拮抗剂付出了巨大努力。本综述反映了1999年至2002年该领域的研究情况。